Comparative safety of sulfonylurea therapies on cardiovascular and severe hypoglycemia outcomes among adults with type 2 diabetes and moderate cardiovascular risk: a target trial emulation - PubMed
6 hours ago
- #Sulfonylurea Safety
- #Cardiovascular Risk
- #Diabetes
- Study compares safety of sulfonylurea therapies (glimepiride, glipizide, glyburide) in adults with type 2 diabetes and moderate cardiovascular risk.
- Primary outcomes measured were major adverse cardiovascular events (MACE) and severe hypoglycemia.
- Results show glimepiride associated with lowest MACE risk, while glipizide linked to lowest severe hypoglycemia risk.
- Glyburide had higher MACE and severe hypoglycemia risks compared to other sulfonylureas.
- Study uses claims data from Optum Labs Data Warehouse and Medicare fee-for-service 100% sample.
- Inverse probability of treatment weighting (IPTW) applied for analysis.
- Findings can guide treatment selection when sulfonylureas are used for glucose-lowering.